CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$16.70
−4.95%0
Insider buys (3m)
8
Insider sells (3m)
-$1.0M
Net value (3m)
+48.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 3, 2026 | Stengone Carmine N. · director, officer: CEO and President | M-Exempt | 2,500 | $1.01 |
| Aug 3, 2026 | Stengone Carmine N. · director, officer: CEO and President | Sale | 2,500 | $16 |
| Jul 10, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | M-Exempt | 25 | $1.01 |
| Jul 10, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 25 | $16 |
| Jul 10, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | M-Exempt | 1,015 | $1.01 |
| Jul 8, 2026 | Stengone Carmine N. · director, officer: CEO and President | M-Exempt | 2,500 | $1.01 |
| Jul 8, 2026 | Stengone Carmine N. · director, officer: CEO and President | Sale | 2,500 | $16 |
| Jul 2, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | M-Exempt | 28,826 | $1.01 |
| Jul 2, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 2,501 | $16 |
| Jul 2, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 5,852 | $16 |
| Jul 2, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | M-Exempt | 4,183 | $1.01 |
| Jul 2, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 28,826 | $16 |
| Jul 1, 2026 | Watkins Tim · officer: CMO & Head of Development | M-Exempt | 10,833 | $4.50 |
| Jul 1, 2026 | Stengone Carmine N. · director, officer: CEO and President | Sale | 10,000 | $16 |
| Jul 1, 2026 | Stengone Carmine N. · director, officer: CEO and President | M-Exempt | 2,500 | $1.26 |
| Jul 1, 2026 | Stengone Carmine N. · director, officer: CEO and President | M-Exempt | 7,500 | $1.01 |
| Jul 1, 2026 | Watkins Tim · officer: CMO & Head of Development | Sale | 10,833 | $16 |
| Jun 26, 2026 | Brady Todd R. · director | A-Award | 19,000 | $14 |
| Jun 26, 2026 | Boyce Sarah · director | A-Award | 19,000 | $14 |
| Jun 26, 2026 | Ignelzi Troy A. · director | A-Award | 19,000 | $14 |
| Jun 26, 2026 | Schimmelpennink Evert B. · director | A-Award | 19,000 | $14 |
| Jun 26, 2026 | Ware Olivia C · director | A-Award | 19,000 | $14 |
| Jun 26, 2026 | Lyons-Williams Lori · director | A-Award | 19,000 | $14 |
| Jun 26, 2026 | Miralles Gines Diego · director | A-Award | 19,000 | $14 |
| Jun 1, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 4,170 | $13 |
| May 1, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 300 | $14 |
| May 1, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 3,870 | $13 |
| Apr 6, 2026 | Lorrain Daniel S. · officer: Chief Scientific Officer | Sale | 4,170 | $13 |
| Mar 2, 2026 | Watkins Tim · officer: CMO & Head of Development | Sale | 3,611 | $15 |
| Mar 2, 2026 | Watkins Tim · officer: CMO & Head of Development | M-Exempt | 3,611 | $4.50 |
Institutional positioning
13F filings over the trailing two quarters
New 22Increased 31Reduced 23Sold out 87
| Filer | Action | Shares | Filed |
|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | Unchanged | 2,841,334 | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 2,734,836 | May 18, 2026 |
| JOHNSON & JOHNSON | Unchanged | 1,979,173 | Mar 18, 2026 |
| JOHNSON & JOHNSON | Reduced | 1,979,173 | May 13, 2026 |
| FRANKLIN RESOURCES INC | Reduced | 1,839,227 | May 13, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Reduced | 1,685,635 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,535,449 | May 15, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 1,420,838 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Reduced | 1,296,012 | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Reduced | 1,255,592 | May 29, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,214,173 | May 15, 2026 |
| FMR LLC | Unchanged | 814,871 | May 15, 2026 |
| IKARIAN CAPITAL, LLC | Increased | 807,874 | May 15, 2026 |
| GREAT POINT PARTNERS LLC | Increased | 800,198 | May 15, 2026 |
| LONGAEVA PARTNERS L.P. | Increased | 732,088 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 3, 2026